tbuckley/cabot-search huggingface dataset:
Acute Myocardial Infarction or Not?
Authors: Chuan-Hai Zhang, Ting-Ting Li, Xiaohong Chen
Journal: JAMA Internal Medicine (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Measuring patient-relevant benefits in the treatment of psoriasis with the Patient Benefit Index: development and preliminary validation of a 10-item short form
Authors: Christine Blome, Catharina C. von Stülpnagel, Matthias Augustin, Ulrich Mrowietz, Kristian Reich, Holger Muehlan, Natalia Kirsten, Anna K. Langenbruch, Christina Sorbe, Toni M. Klein
Journal: British Journal of Dermatology (2022)
Analysis of an Intervention for Emergency Medical Services Personnel to Reduce Epinephrine Dosing Errors in Infants
Authors: Matt Hansen, Grace Walker-Stevenson, Carl Eriksson, Garth Meckler, Tabria Harrod, Nathan Bahr, Jeanne-Marie Guise
Journal: JAMA Network Open (2022)

This quality improvement study investigates whether a simulation-driven emergency medical services protocol of using a 1-mL syringe to administer small epinephrine doses could reduce dosing errors in infants.
The effect of biofeedback pelvic floor training with ACTICORE1 on fecal incontinence A prospective multicentric cohort pilot study
Authors: C. Paasch, L. Bruckert, S. Soeder, J. Von Frankenberg, R. Mantke, E. Lorenz, M. Andric, A. Wiede, A. Strack, M. Hünerbein, S. Croner
Journal: International Journal of Surgery (2022)
Acute Upper Airway Disease in Children With the Omicron (B.1.1.529) Variant of SARS-CoV-2—A Report From the US National COVID Cohort Collaborative
Authors: Blake Martin, Peter E. DeWitt, Seth Russell, L. Nelson Sanchez-Pinto, Melissa A. Haendel, Richard Moffitt, Tellen D. Bennett
Journal: JAMA Pediatrics (2022)

This cohort study uses data from the US National COVID Cohort Collaborative to evaluate upper airway infections in children during the surge of the Omicron (B.1.1.529) variant of SARS-CoV-2 in the US.
Cerebral Hemorrhage: Pathophysiology, Treatment, and Future Directions
Authors: Jessica Magid-Bernstein, Romuald Girard, Sean Polster, Abhinav Srinath, Sharbel Romanos, Issam A. Awad, Lauren H. Sansing
Journal: Circulation Research (2022)

Intracerebral hemorrhage (ICH) is a devastating form of stroke with high morbidity and mortality. This review article focuses on the epidemiology, cause, mechanisms of injury, current treatment strategies, and future research directions of ICH. Incidence of hemorrhagic stroke has increased worldwide over the past 40 years, with shifts in the cause over time as hypertension management has improved and anticoagulant use has increased. Preclinical and clinical trials have elucidated the underlying ICH cause and mechanisms of injury from ICH including the complex interaction between edema, inflammation, iron-induced injury, and oxidative stress. Several trials have investigated optimal medical and surgical management of ICH without clear improvement in survival and functional outcomes. Ongoing research into novel approaches for ICH management provide hope for reducing the devastating effect of this disease in the future. Areas of promise in ICH therapy include prognostic biomarkers and primary prevention based on disease pathobiology, ultra-early hemostatic therapy, minimally invasive surgery, and perihematomal protection against inflammatory brain injury.
Neutrophil inhibition improves acute inflammation in a murine model of viral myocarditis
Authors: Paolo Carai, Laura Florit González, Stijn Van Bruggen, Valerie Spalart, Daria De Giorgio, Nadéche Geuens, Kimberly Martinod, Elizabeth Anne Vincent Jones, Stephane Heymans
Journal: Cardiovascular Research (2022)

Viral myocarditis (VM) is an inflammatory pathology of the myocardium triggered by a viral infection that may cause sudden death or heart failure (HF), especially in the younger population. Current treatments only stabilize and improve cardiac function without resolving the underlying inflammatory cause. The factors that induce VM to progress to HF are still uncertain, but neutrophils have been increasingly associated with the negative evolution of cardiac pathologies. The present study investigates the contribution of neutrophils to VM disease progression in different ways.
Analysis of Variation in Organizational Definitions of Primary Care Panels
Authors: Michael F. Mayo-Smith, Rebecca A. Robbins, Mark Murray, Rachel Weber, Pamela J. Bagley, Elaina J. Vitale, Neil M. Paige
Journal: JAMA Network Open (2022)

<h3>Importance</h3> Primary care panel size plays an increasing role in measuring primary care provider (ie, physicians and advanced practice providers, which include nurse practitioners and physician assistants) workload, setting practice capacity, and determining pay and can influence quality of care, access, and burnout. However, reported panel sizes vary widely. <h3>Objective</h3> To identify how panels are defined, the degree of variation in these definitions, the consequences of different definitions of panel size, and research on strengths of different approaches. <h3>Evidence Review</h3> Following Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines, MEDLINE, Web of Science, Embase, and Dissertations and Theses Global databases were searched from inception to April 28, 2021, for subject headings and text words to capture concepts of primary care panel size. Article review and data abstraction were performed independently by 2 reviewers. Main outcomes reported included rules for adding or removing patients from panels, rules for measuring primary care provider resources, consequences of different rules on reported panel size, and research on advantages and disadvantages of different rules. <h3>Findings</h3> The literature search yielded 1687 articles, with 294 potentially relevant articles and 74 containing relevant data. Specific practices were identified from 29 health care systems and 5 empanelment implementation guides. Patients were most commonly empaneled after 1 primary care visit (24 of 34 [70.6%]), but some were empaneled only after several visits (5 [14.8%]), enrollment in a health plan (4 [11.8%]) or any visit to the health care system (1 [3.0%]). Patients were removed when no visit had occurred in a specified look-back period, which varied from 12 to 42 months. Regarding primary care provider resources, half of organizations assigned advanced practice providers independent panels and half had them share panels with a physician, increasing the physician's panel by 50% to 100%. Analyses demonstrated that changes in individual rules for adding patients, removing patients, or estimating primary care provider resources could increase reported panel size from 20% to 100%, without change in actual primary care provider workload. No research was found investigating advantages of different definitions. <h3>Conclusions and Relevance</h3> Much variation exists in how panels are defined, and this variation can have substantial consequences on reported panel size. Research is needed on how to define primary care panels to best identify active patients, which could contribute to a widely accepted standard approach to panel definition.
Author Correction: Homeostatic IL-13 in healthy skin directs dendritic cell differentiation to promote TH2 and inhibit TH17 cell polarization
Authors: Johannes U. Mayer, Kerry L. Hilligan, Jodie S. Chandler, David A. Eccles, Samuel I. Old, Rita G. Domingues, Jianping Yang, Greta R. Webb, Luis Munoz-Erazo, Evelyn J. Hyde, Kirsty A. Wakelin, Shiau-Choot Tang, Sally C. Chappell, Sventja von Daake, Frank Brombacher, Charles R. Mackay, Alan Sher, Roxane Tussiwand, Lisa M. Connor, David Gallego-Ortega, Dragana Jankovic, Graham Le Gros, Matthew R. Hepworth, Olivier Lamiable, Franca Ronchese
Journal: Nature Immunology (2022)
Oncolytic virus–mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice
Authors: Laura Evgin, Tim Kottke, Jason Tonne, Jill Thompson, Amanda L. Huff, Jacob van Vloten, Madelyn Moore, Josefine Michael, Christopher Driscoll, Jose Pulido, Eric Swanson, Richard Kennedy, Matt Coffey, Houra Loghmani, Luis Sanchez-Perez, Gloria Olivier, Kevin Harrington, Hardev Pandha, Alan Melcher, Rosa Maria Diaz, Richard G. Vile
Journal: Science Translational Medicine (2022)

Oncolytic viruses (OVs) encoding a variety of transgenes have been evaluated as therapeutic tools to increase the efficacy of chimeric antigen receptor (CAR)–modified T cells in the solid tumor microenvironment (TME). Here, using systemically delivered OVs and CAR T cells in immunocompetent mouse models, we have defined a mechanism by which OVs can potentiate CAR T cell efficacy against solid tumor models of melanoma and glioma. We show that stimulation of the native T cell receptor (TCR) with viral or virally encoded epitopes gives rise to enhanced proliferation, CAR-directed antitumor function, and distinct memory phenotypes. In vivo expansion of dual-specific (DS) CAR T cells was leveraged by in vitro preloading with oncolytic vesicular stomatitis virus (VSV) or reovirus, allowing for a further in vivo expansion and reactivation of T cells by homologous boosting. This treatment led to prolonged survival of mice with subcutaneous melanoma and intracranial glioma tumors. Human CD19 CAR T cells could also be expanded in vitro with TCR reactivity against viral or virally encoded antigens and was associated with greater CAR-directed cytokine production. Our data highlight the utility of combining OV and CAR T cell therapy and show that stimulation of the native TCR can be exploited to enhance CAR T cell activity and efficacy in mice.
Clinical Utility Assessment of Gonadotropin-Releasing Hormone Analogs Among Women Younger Than 35 Years
Authors: Zachary R. McCaw, Lee-Jen Wei
Journal: JAMA Oncology (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
CD45RA <sup>+</sup> CD62L <sup>−</sup> ILCs in human tissues represent a quiescent local reservoir for the generation of differentiated ILCs
Authors: Efthymia Kokkinou, Ram Vinay Pandey, Luca Mazzurana, Irene Gutierrez-Perez, Christopher Andrew Tibbitt, Whitney Weigel, Tea Soini, Anna Carrasco, Anna Rao, Maho Nagasawa, Suzanne M. Bal, Mattias Jangard, Danielle Friberg, Ulrik Lindforss, Caroline Nordenvall, Malin Ljunggren, Staffan Haapaniemi, Åsa V. Keita, Johan Söderholm, Charlotte Hedin, Hergen Spits, Yenan T. Bryceson, Jenny Mjösberg
Journal: Science Immunology (2022)

Innate lymphoid cells (ILCs) are highly plastic and predominantly mucosal tissue-resident cells that contribute to both homeostasis and inflammation depending on the microenvironment. The discovery of naïve-like ILCs suggests an ILC differentiation process that is akin to naïve T cell differentiation. Delineating the mechanisms that underlie ILC differentiation in tissues is crucial for understanding ILC biology in health and disease. Here, we showed that tonsillar ILCs expressing CD45RA lacked proliferative activity, indicative of cellular quiescence. CD62L distinguished two subsets of CD45RA + ILCs. CD45RA + CD62L + ILCs (CD62L + ILCs) resembled circulating naïve ILCs because they lacked the transcriptional, metabolic, epigenetic, and cytokine production signatures of differentiated ILCs. CD45RA + CD62L − ILCs (CD62L − ILCs) were epigenetically similar to CD62L + ILCs but showed a transcriptional, metabolic, and cytokine production signature that was more akin to differentiated ILCs. CD62L + and CD62L − ILCs contained uni- and multipotent precursors of ILC1s/NK cells and ILC3s. Differentiation of CD62L + and CD62L − ILCs led to metabolic reprogramming including up-regulation of genes associated with glycolysis, which was needed for their effector functions after differentiation. CD62L − ILCs with preferential differentiation capacity toward IL-22–producing ILC3s accumulated in the inflamed mucosa of patients with inflammatory bowel disease. These data suggested distinct differentiation potential of CD62L + and CD62L − ILCs between tissue microenvironments and identified that manipulation of these cells is a possible approach to restore tissue-immune homeostasis.
What Is Osteoarthritis?
Authors: Linda Yue, Jessica Berman
Journal: JAMA (2022)

What Is Osteoarthritis?Osteoarthritis (OA) is a type of arthritis that causes joint pain and impairment of function.Although OA has commonly been attributed to the "wear and tear" of aging, it is now understood as a complex disease involving breakdown of cartilage between bones, bone remodeling, and joint inflammation.Although OA can involve any joint in the body, the joints most frequently affected are the hips, knees, feet, and hands.Osteoarthritis is the most common type of arthritis and affects an estimated 32 million people in the US and more than 240 million people worldwide.
Reporting ChAracteristics of cadaver training and sUrgical studies: The CACTUS guidelines
Authors: Guglielmo Mantica, Rosario Leonardi, Raquel Diaz, Rafaela Malinaric, Stefano Parodi, Stefano Tappero, Irene Paraboschi, Mario Álvarez-Maestro, Jeremy Yuen-Chun Teoh, Massimo Garriboli, Luis Enrique Ortega Polledo, Domenico Soriero, Davide Pertile, Davide De Marchi, Giovannalberto Pini, Lorenzo Rigatti, Sanjib Kumar Ghosh, Oluwanisola Akanji Onigbinde, Alessandro Tafuri, Diego M Carrion, Sven Nikles, Anna Antoni, Pietro Fransvea, Francesco Esperto, Fernando A.M. Herbella, Andrea Oxley da Rocha, Vicente Vanaclocha, Luis Sánchez-Guillén, Bruce Wainman, Alejandro Quiroga-Garza, Piero Fregatti, Federica Murelli, André Van der Merwe, Juan Gomez Rivas, Carlo Terrone
Journal: International Journal of Surgery (2022)
The last-minute redemption of inflammatory cells in lung repair
Authors: Paula Martín-Vicente, Cecilia López-Martínez, Guillermo M. Albaiceta
Journal: European Respiratory Journal (2022)

<b>Inflammatory cells play a key role in lung repair after acute injury. These cells switch to a pro-repair phenotype over time in response to extracellular signals. Among these, VEGF-C promotes neutrophil clearance (efferocytosis) in macrophages.</b>https://bit.ly/3KixGnX
Are We Finally Ready for the Widespread Adoption of Stereotactic Radiation in Gynecologic Cancers?
Authors: Vonetta M. Williams, Onyinye Balogun, Kaled Alektiar
Journal: JAMA Oncology (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Functional coupling of TRPM2 and extrasynaptic NMDARs exacerbates excitotoxicity in ischemic brain injury
Authors: Pengyu Zong, Jianlin Feng, Zhichao Yue, Yunfeng Li, Gongxiong Wu, Baonan Sun, Yanlin He, Barbara Miller, Albert S. Yu, Zhongping Su, Jia Xie, Yasuo Mori, Bing Hao, Lixia Yue
Journal: Neuron (2022)
Prone Positioning for Nonintubated Patients With COVID-19—Potential Dangers of Extrapolation and Intermediate Outcome Variables
Authors: Peter D. Sottile, Richard K. Albert, Marc Moss
Journal: JAMA Internal Medicine (2022)

Edward Tang Qian, MD; Cheryl L. Gatto, PhD; Olga Amusina, DNP; Mary Lynn Dear, PhD; William Hiser, BA; Reagan Buie, MHA; Sunil Kripalani, MD; Frank E. Harrell Jr, PhD; Robert E. Freundlich, MD, MS, MSCI; Yue Gao, MS; Wu Gong, MD, MS; Cassandra Hennessy, MS; Jillann Grooms, MSN; Megan Mattingly, MSN; Shashi K. Bellam, MD; Jessica Burke, MD; Arwa Zakaria, DO; Eduard E. Vasilevskis, MD; Frederic T. Billings IV, MD, MSc; Jill M. Pulley, MBA; Gordon R. Bernard, MD; Christopher J. Lindsell, PhD; Todd W. Rice, MD, MSc; Vanderbilt Learning Healthcare System Platform Investigators; Robert Dittus; Shon Dwyer; Paul Harris; Tina Hartert; Jim Hayman; Catherine Ivory; Kevin Johnson; Ruth Kleinpell; Lee Ann Liska; Patrick Luther; Jay Morrison; Thomas Nantais; Mariann Piano; Kris Rhem; Russell Rothman; Matt Semler; Robin Steaban; Philip Walker; Consuelo Wilkins; Adam Wright ; Autumn Zuckerman
Age-associated callus senescent cells produce TGF-β1 that inhibits fracture healing in aged mice
Authors: Jiatong Liu, Jun Zhang, Xi Lin, Brendan F. Boyce, Hengwei Zhang, Lianping Xing
Journal: Journal of Clinical Investigation (2022)

Cellular senescence plays an important role in human diseases, including osteoporosis and osteoarthritis. Senescent cells (SCs) produce the senescence-associated secretory phenotype to affect the function of neighboring cells and SCs themselves. Delayed fracture healing is common in the elderly and is accompanied by reduced mesenchymal progenitor cells (MPCs). However, the contribution of cellular senescence to fracture healing in the aged has not to our knowledge been studied. Here, we used C57BL/6J 4-month-old young and 20-month-old aged mice and demonstrated a rapid increase in SCs in the fracture callus of aged mice. The senolytic drugs dasatinib plus quercetin enhanced fracture healing in aged mice. Aged callus SCs inhibited the growth and proliferation of callus-derived MPCs (CaMPCs) and expressed high levels of TGF-β1. TGF-β-neutralizing Ab prevented the inhibitory effects of aged callus SCs on CaMPCs and promoted fracture healing in aged mice, which was associated with increased CaMPCs and proliferating cells. Thus, fracture triggered a significant cellular senescence in the callus cells of aged mice, which inhibited MPCs by expressing TGF-β1. Short-term administration of dasatinib plus quercetin depleted callus SCs and accelerated fracture healing in aged mice. Senolytic drugs represent a promising therapy, while TGF-β1 signaling is a molecular mechanism for fractures in the elderly via SCs.
Alcohol use disorder in community management of chronic liver diseases
Authors: Lorenzo Leggio, Jessica L. Mellinger
Journal: Hepatology (2022)

Rising rates of alcohol use disorder (AUD) combined with increases in alcohol‐related liver disease (ALD) and other liver disease have resulted in the need to develop alcohol management strategies at all levels of patient care. For those with pre‐existing liver disease, whether ALD or others, attention to alcohol use treatment and abstinence becomes critical to avoiding worsening liver‐related consequences. Modalities to help patients reduce or stop alcohol include screening/brief intervention/referral to treatment, various therapeutic modalities including cognitive behavioral therapy, motivational enhancement therapy and 12‐step facilitation, and alcohol relapse prevention medications. Harm reduction approaches versus total abstinence may be considered, but for those with existing ALD, particularly advanced ALD (cirrhosis or acute alcoholic hepatitis), total abstinence from alcohol is the recommendation, given clear data that ongoing alcohol use worsens mortality and liver‐related morbidity. For certain populations, alcohol cessation is even more critically important. For those with hepatitis C or NAFLD, alcohol use accelerates negative liver‐related outcomes. In women, alcohol use accelerates liver damage and results in worsened liver‐related mortality. Efforts to integrate AUD and liver disease care are urgently needed and can occur at several levels, with establishment of multidisciplinary ALD clinics for fully integrated co‐management as an important goal.
Immunotherapy of Neuroblastoma: Facts and Hopes
Authors: John Anderson, Robbie G. Majzner, Paul M. Sondel
Journal: Clinical Cancer Research (2022)

Abstract While the adoption of multimodal therapy including surgery, radiation, and aggressive combination chemotherapy has improved outcomes for many children with high-risk neuroblastoma, we appear to have reached a plateau in what can be achieved with cytotoxic therapies alone. Most children with cancer, including high-risk neuroblastoma, do not benefit from treatment with immune checkpoint inhibitors (ICI) that have revolutionized the treatment of many highly immunogenic adult solid tumors. This likely reflects the low tumor mutation burden as well as the downregulated MHC-I that characterizes most high-risk neuroblastomas. For these reasons, neuroblastoma represents an immunotherapeutic challenge that may be a model for the creation of effective immunotherapy for other “cold” tumors in children and adults that do not respond to ICI. The identification of strong expression of the disialoganglioside GD2 on the surface of nearly all neuroblastoma cells provided a target for immune recognition by anti-GD2 mAbs that recruit Fc receptor–expressing innate immune cells that mediate cytotoxicity or phagocytosis. Adoption of anti-GD2 antibodies into both upfront and relapse treatment protocols has dramatically increased survival rates and altered the landscape for children with high-risk neuroblastoma. This review describes how these approaches have been expanded to additional combinations and forms of immunotherapy that have already demonstrated clear clinical benefit. We also describe the efforts to identify additional immune targets for neuroblastoma. Finally, we summarize newer approaches being pursued that may well help both innate and adaptive immune cells, endogenous or genetically engineered, to more effectively destroy neuroblastoma cells, to better induce complete remission and prevent recurrence.